The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.
- Record monthly revenue of $910,767, highest in company history
- Wholesale channel hits $340,131, surpassing FY25 annual wholesale sales in half a year
- Strong growth across Australian grocery, US Amazon, and B2B ingredient sales
- US FDA regulatory clarity supports expanded kava product distribution
- Company advancing toward breakeven with farm-to-shelf strategy
Record-Breaking Sales Momentum
The Calmer Co. International Limited (ASX, CCO), a specialist in kava-based natural relaxation products, has announced a landmark achievement with December 2025 sales reaching $910,767, the highest monthly revenue since its ASX listing. This milestone underscores the company’s accelerating growth trajectory and validates its strategic focus on diversified sales channels and product formats.
Wholesale Channel Leads the Charge
The wholesale segment was a standout performer, generating $340,131 in revenue for December alone. Remarkably, the year-to-date wholesale sales have already exceeded the entire fiscal year 2025’s wholesale revenue, signalling robust demand for The Calmer Co.’s high-kavalactone kava extracts among global partners. This surge reflects the company’s successful penetration into B2B markets and its vertically integrated farm-to-shelf supply chain, which ensures product quality and traceability.
Expanding Footprint in Australia and the US
Australian retail sales remain strong, buoyed by distribution through major grocery chains Coles and Woolworths under the Fiji Kava brand. Meanwhile, the US market is gaining momentum, particularly through Amazon where the company has broadened its product range to include tinctures, capsules, and flavoured kava shots. This growth is further supported by recent regulatory developments in the US, where the Food and Drug Administration has clarified that traditionally prepared kava beverages are classified as food, providing a clearer compliance pathway and reducing market uncertainty.
Regulatory Clarity Fuels Confidence
Founder and CEO Zane Yoshida highlighted the significance of the FDA’s decision, noting it de-risks the company’s expansion in the world’s largest consumer market. The dual regulatory framework, distinguishing traditionally brewed beverages from dietary supplements, aligns well with The Calmer Co.’s multi-format portfolio strategy. This clarity is expected to facilitate broader retail distribution and accelerate digitally-led growth in the US.
Path Toward Sustainable Profitability
The record sales performance and improving channel mix contribute to a healthier margin profile, positioning The Calmer Co. on a clear path toward breakeven and sustainable profitability in fiscal year 2026. The company’s integrated approach, from farming through to retail shelf, continues to underpin its competitive advantage in the natural relaxation and alcohol alternative market segments.
Bottom Line?
With regulatory headwinds easing and sales channels firing on all cylinders, The Calmer Co. is poised for a pivotal year ahead.
Questions in the middle?
- Will the company sustain wholesale growth momentum beyond FY26 first half?
- How will evolving US regulations impact product innovation and market access?
- What are the competitive risks as kava gains mainstream consumer attention?